Zobrazeno 1 - 10
of 107
pro vyhledávání: ''
Publikováno v:
Value Health
Adjuvant chemotherapy is not recommended for patients with average-risk stage II (T3N0) colon cancer. Nevertheless, a subgroup of these patients who are CDX2-negative might benefit from adjuvant chemotherapy. We evaluated the cost-effectiveness of te
Autor:
Ana Paula Martins, A.R. Godinho, Rui Marques, A. Quintela, H.L. Pais, P. Heudtlass, da Cruz Jp Lopes
Publikováno v:
Value in Health. 24:S21
Autor:
Ravit Geva, Ayala Hubert, Alexander Gluzman, Baruch Brenner, Ygael Dror, Einat Shacham-Shmueli, Lior Soussan-Gutman, Moshe Mishaeli, Ofer Purim, Haluk Tezcan, Alexander Beny, Efraim Idelevich, Sophia Man, Nicky Liebermann, Calvin Chao, Mariana Steiner, Adi Shani, Katerina Shulman, Megan P. Rothney
Publikováno v:
Value in Health. 19(1):82-87
ObjectivesTo evaluate the impact of the 12-gene Colon Cancer Recurrence Score Assay—a clinically validated prognosticator in stage II colon cancer after surgical resection—on adjuvant treatment decisions in T3 mismatch repair proficient (MMR-P) s
Publikováno v:
Value in Health. 23:S42
Publikováno v:
Value in Health. 23:S133
Publikováno v:
Value in Health. 22:S467
Publikováno v:
Value in Health. 21:S31-S32
Publikováno v:
Value in Health. 22:S96
Autor:
M.E.S.A.A. Abdel-Aty
Publikováno v:
Value in Health. 22:S68
Publikováno v:
Value in Health. 21:S11